************************************
Brakke Consulting’s
Animal Health News & Notes for November 25, 2009
Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon, DVM, MBA
************************************
IN THE NEWS:
Brakke news
Animal Health Industry History Book
earnings news
Central Garden & Pet
Pilgrims Pride
Tyson Foods
other news
Boehringer Ingelheim Vetmedica
Chanelle Veterinary
DSM
Immunovaccine
Novozymes
Pfizer
Provimi Animal Nutrition India
Quantum Immunologics
Vetcare
************************************
LOOKING FOR HOLIDAY GIFT IDEAS?
Copies of Brakke Consulting’s recently-published book chronicling the history of the US animal health industry are still available! Reasonably priced at $35 per copy, these gift-quality books make great holiday gifts for employees and clients.
For more information on The U.S. Animal Health Industry: Its pioneers and legacy of innovation, visit our website at www.BrakkeConsulting.com or contact Jane Morgan at jmorgan@brakkeconsulting.com
************************************
COMPANY EARNINGS RELEASES
> Central Garden & Pet Company announced full year results for the fourth quarter ended September 26, 2009. Net sales for the Pet Products segment in the quarter were $204 million, a decrease of 10% compared to the year ago period. (Business Wire)
> Tyson Foods reported results for the full year ended October 3, 2009. The company reported a net loss of ($537 million) compared with a profit of $86 million in fiscal 2008. Sales dipped to $26.7 billion from about $26.9 billion. (Meating Place)
> Pilgrim’s Pride reported results for its full fiscal year. The company reported a net loss of ($152 million) on net sales of $7.1 billion in 2009, compared with a net loss of ($999 million) on net sales of $8.5 billion for the full year in 2008. (Meating Place)
************************************
COMPANY NEWS RELEASES
> Immunovaccine Inc. announced the signing of an exclusive, worldwide license agreement with Pfizer Animal Health for Immunovaccine’s patented vaccine delivery technology. Pfizer Animal Health said it plans to develop enhanced cattle vaccines incorporating Immunovaccine’s technology. Terms were not disclosed. (Eathtimes.org)
> Boehringer Ingelheim Vetmedica, Inc. (BIVI), announced the introduction of its Vetera West Nile virus family of vaccines, the only vaccines containing the North American Equine E159 2005 horse isolate. The Vetera family of vaccines includes protection against West Nile virus; Eastern, Western and Venezuelan equine encephalomyelitis; and tetanus, in a variety of combinations. (company press release)
> Quantum Immunologics, Inc. announced that it has entered into a Collaboration Agreement with Auburn University to form a new, jointly-owned company to bring its novel cancer immunotherapy to the veterinary market. Along with providing corporate and administrative management of the new company, Quantum will license its proprietary oncofetal antigen-based therapy to serve as the collaboration’s underlying technology. (SYS-CON Media)
> EU Chanelle Veterinary announced it has received EU clearance for two veterinary products. Ivermectin Oral for sheep was launched as part of its Animec branded range; the company also introduced new pork flavored, chewable meloxicam tablets for dogs. (Animal Pharm)
> EU DSM Nutritional Products and Novozymes announced the European launch of Ronozyme NP, a phytase product for use in poultry and pig diets. (Animal Pharm)
> INDIA Vetcare has been renamed as Provimi Animal Nutrition India, following Provimi’s acquisition of 100% of the shares in Vetcare last April. (Animal Pharm)
************************************
BRAKKE CONSULTING VIEWPOINT
All of us at Brakke Consulting want to wish each of our subscribers and clients a Happy Thanksgiving!
Ron Brakke
Joel Adamson
Ken Berkholtz
Ray Collier
Lynn Fondon
Atsuo Hata
Jay Lockhart
John Mannhaupt
Susan Mannhaupt
Christine Merle
Richard Miles
Jane Morgan
Kevin Scott
John Volk
************************************
This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting’s services and syndicated studies, visit our website at www.brakkeconsulting.com.
Brakke Consulting, Inc.
2735 Villa Creek, Suite 140
Dallas, TX 75234 USA
English (United States) 
Portuguese